<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1996">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638583</url>
  </required_header>
  <id_info>
    <org_study_id>HS-17-00746</org_study_id>
    <secondary_id>R01AG053798</secondary_id>
    <nct_id>NCT03638583</nct_id>
  </id_info>
  <brief_title>Alzheimer Prevention Trials (APT) Webstudy</brief_title>
  <official_title>Alzheimer Prevention Trials (APT) Webstudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the Alzheimer Prevention Trials (APT) Webstudy is to accelerate enrollment for&#xD;
      Alzheimer's disease (AD) clinical trials by identifying and tracking individuals who may be&#xD;
      at higher risk for developing AD dementia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The APT Webstudy will use web-based cognitive testing and questionnaires to generate a risk&#xD;
      score which will be used to identify individuals who may be at an increased risk for&#xD;
      developing AD dementia.&#xD;
&#xD;
      Individuals who join the APT Webstudy will register at https://www.aptwebstudy.org/, sign an&#xD;
      electronic informed consent form (ICF), provide basic demographic information and participate&#xD;
      in web-based cognitive testing. Participants will return the APT Webstudy quarterly (every 3&#xD;
      months) to complete the cognitive testing again.&#xD;
&#xD;
      Based on the risk score and changes identified in the cognitive testing results, participants&#xD;
      will be invited to visit a partnering clinical trial site for an in-person visit with&#xD;
      biomarker testing and clinical assessment.&#xD;
&#xD;
      The combined results of the web-based assessments, with the biomarker and clinical&#xD;
      assessments, will allow an adaptive statistical algorithm to improve the selection of those&#xD;
      at highest risk for developing AD.&#xD;
&#xD;
      To Join the APT Webstudy, please visit https://www.aptwebstudy.org/.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Enrollment into Alzheimer's prevention research studies</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Referral into prevention research studies</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of individuals enrolled into Alzheimer's prevention studies</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200000</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Anyone who meets entry criteria is eligible to join the Webstudy. We anticipate 200,000&#xD;
        individuals will join.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female at least 50 years of age&#xD;
&#xD;
          -  no evidence of dementia&#xD;
&#xD;
          -  willing to participate in remote longitudinal cognitive testing and possible referral&#xD;
             for biomarker assessment based on risk&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  N/A. Anyone can register for the APT Webstudy, however, only individuals identified&#xD;
             using the risk algorithm will be referred for in-person biomarker assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Aisen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC ATRI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reisa Sperling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Cummings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>APT Webstudy Team</last_name>
    <phone>858-877-3135</phone>
    <email>info@aptwebstudy.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Https://Www.Aptwebstudy.Org</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>APT Webstudy Team</last_name>
      <phone>858-877-3135</phone>
      <email>info@aptwebstudy.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>October 19, 2022</last_update_submitted>
  <last_update_submitted_qc>October 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Aisen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>Prevention</keyword>
  <keyword>Web-Based</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

